



<b>INFORMATION DISCLOSURE CITATION</b> <b>PTO-1449</b> 		ATTY. DOCKET NO. 25352-0033 D1		SERIAL NO. 10/716,652			
		APPLICANT Edgardo Laborde et al.					
		FILING DATE 11/18/2003		GROUP Not Assigned			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
B/D	* 3,823,144	07/09/1974	Schmitt et al.	544	377	06/21/1972	
B/D	* 4,269,990	05/26/1981	May et al.	548	315	12/05/1979	
B/D	* 5,977,108	11/02/1999	Kikuchi et al.	514	249	06/27/1996	
B/D	* 6,140,338	10/2000	Naya et al	514	299		
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
B/D	* 2 001 284	09/26/2969	FR	A 61 K	21/00		
B/D	* 1 250 611	10/28/1974	GB	C07D	99/22		
B/D	* 9-255572	09/1997	Japan				
B/D	00/46198	08/2000	PCT				
B/D	* 01/57021	08/09/2001	PCT	C07D	401/14		
B/D	* 01/57003	08/09/2001	PCT	C07D	265/36		
B/D	* 01/57044	08/2001	PCT				
B/D	* 92/14710	09/03/1992	PCT	C07D	211/26		
B/D	* 97/24325	07/1997	PCT				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
B/D	* Alam et al., "Increased MCP-1, RANTES, and MIP-1 $\alpha$ in Bronchoalveolar Lavage Fluid of Allergic Asthmatic Patients", <i>Am J Respir Crit Care Med</i> , 153:1398-1404. (1996)						
B/D	* Alcamì et al., "Blockade of Chemokine Activity by a Soluble Chemokine Binding Protein form Vaccinia Virus", <i>J Immunol</i> , 160:624-633 (1998)						
B/D	* Antoniadès et al., "Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis", <i>Proc Natl Acad Sci USA</i> , 89:5371-5375 (1992)						
B/D	* Ajuebor et al., "Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model", <i>Journal of Leukocyte Biology</i> , vol. 63:108-116, January 1998						
B/D	* Baggiolini et al., "Human Chemokines; an update", <i>Annu rev Immunol</i> (1997), pp. 15:675-705						
B/D	* Baggiolini, "Chemokines and Leukocyte Traffic, <i>Nature</i> vol: 392:9 pp 565-568, (1998)						
EXAMINER		DATE CONSIDERED 6-13-2005					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. 1.98(d).


<b>INFORMATION DISCLOSURE</b> <b>CITATION</b> PTO-1449 DEC 09 2003 U.S. PATENT & TRADEMARK OFFICE		ATTY. DOCKET NO.		SERIAL NO.			
		25352-0033 D1		10/716,652			
		APPLICANT Edgardo Laborde et al.					
		FILING DATE 11/18/2003		GROUP Not Assigned			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
BD	* 6,288,103	09/2001	Faull et al	514	419		
BD	* 6,316,449	11/2001	Bratton et al.	514	252.04		
BD	* 6,329,402	12/11/2001	Kikuchi et al.	514	341	05/17/1999	
BD	* 6,342,516	01/2002	Umeda et al.	514	397		
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
BD	* 97/44329	11/1997	PCT				
BD	* 98/02151	01/1998	PCT				
BD	* 98/04554	05/1999	PCT				
BD	* 98/06703	02/1998	PCT				
BD	* 98/27815	07/1998	PCT				
BD	* 99/40072	08/12/1999	PCT	C07D	235/16		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
BD	* Boring et al., "Decreased lesion formation in CCR2 <sup>-/-</sup> mice reveals a role for chemokines in the initiation of atherosclerosis", <i>Nature</i> , 394:894-897 (1998)						
BD	* Bright et al., "Identification of a Non Peptidic Rantes Antagonist", <i>Bioorg Med Chem Lett</i> , 8:771-774 (1998)						
BD	* Campbell et al., "Monocyte Chemoattractant Protein-1 Mediates Cockroach Allergen-Induced Bronchial Hyperreactivity in Normal but Not CCR2 <sup>-/-</sup> Mice: The Role of Mast Cells", <i>J Immunol</i> , 163:2160-2167 (1999)						
BD	Chemical Abstracts, 103(17), Abst. No. 141873u (1985); Abstract of Kuzdzinski, L. et al: "Synthesis of new 4 and 5 disubstituted isothiazoles" <i>Pol J Pharmacol Pahrn</i> , 36(5):485-491 (1984)						
BD	Chemical Abstracts, 100(21), Abst. No. 174751u (1984): Abstract of Ormek, G. et al., "Ring-opening reactions of potentially biologically active benzothienooxazines" <i>Arc Pharm</i> , 317(2):117-120 (1984)						
BD	* Folkman and Shing, "Control of Angiogenesis by Heparin and Other Sulfated Polysaccharides", <i>Adv Exp Med Biol.</i> , 313:355-364 (1992)						
BD	* Forbes et al., "CCR2B Receptor Antagonists: Conversion of a Weak HTS Hit to a Potent Lead Compound", <i>Bioorg Med Chem. Lett</i> , 10:1803-1806 (2000)						
EXAMINER		B. Kents		DATE CONSIDERED		6/13 - 2005	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).


<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449	ATTY. DOCKET NO. 25352-0033 D1	SERIAL NO. 10/716,652
	APPLICANT Edgardo Laborde et al.	
	FILING DATE 11/18/2003	GROUP Not Assigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
BD	* Gosling et al., "MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that over express human apo37lipoprotein B", <i>J Clin Invest</i> , 103:773-778 (1999)	
BD	* Gu et al., "Absence of Monocyte Chemoattractant Protein-1 Reduces Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Mice", <i>Mol Cell</i> , 2:275-281 (1998)	
BD	* Hesselgesser, "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor", <i>J. Biol Chem</i> , 273:15687-15692 (1998)	
BD	* Hoogewerf et al., "Glycosaminoglycans Mediate Cell Surface Oligomerization of Chemokines", <i>Biochemistry</i> 36:13570-13578, (1997).	
BD	* Hosaka et al., "Expression of the Chemokine Superfamily in Rheumatoid Arthritis", <i>Clin Exp Immunol</i> , 97:451-457. (1994)	
BD	* Hsieh et al., "Immunotherapy Suppresses the Production of monocyte chemotactic and activating factor and augments the production of IL-8 in Children with Asthma", <i>J Allergy Clin Immunol</i> , 98:580-587 (1996)	
BD	* Kitano M. et al., "Synthesis and Biological Activity of N-(Aminoiminomethyl)-1H-Idoleca Rboxamide Inhibitors", <i>Chem and Pharm Bulletin</i> , Pharmaceutical Society of Japan, vol. 47, no. 11, 11/1999, pp 1538.	
BD	* Koch et al., "Enhanced Production of Monocyte Chemoattractant Protein-1 in Rheumatoid Arthritis", <i>J Clin Invest</i> , 90:772-779, (1992)	
BD	* Kunkel et al., "The Role of Chemokines in Inflammatory Joint Disease", <i>J Leukocyte Biol</i> , 59:6-12 (1996)	
BD	* Kurashima et al., "Increase of Chemokine Levels in Sputum Precedes Exacerbation of Acute Asthma Attacks", <i>J Leukocyte Biol</i> , 59:313-316, (1996)	
BD	* Kuschert et al., "Glycosamineoglycans interact selectively with chemokines and modulate receptor binding and cellular responses", <i>Biochemistry</i> 38:12959-12968, (1999).	
BD	* Liang et al., "Identification and characterization of a potent, selective and orally active antagonist of the cc chemokine receptor-1", <i>The Journal of Biological Chemistry</i> , vol. 25:19000-19008, June 23, 2000.	
BD	* Luster, "Chemokines Chemotactic Cytokines That Mediate Inflammation", <i>The New England Journal of Medicine</i> , pp. 436-445, February 12, 1998	
BD	* McFadden and Kelvin, "New Strategies for Chemokine Inhibition and Modulation", <i>Biochem Pharmacol</i> , 54:1271-1280 (1997)	
BD	* Mirzadegan et al., "Identification of the binding site for a novel class of CCR2bchemokine receptor antagonists...", <i>The American Society for Biochemistry and Molecular Biology, Inc.</i> , manuscript M000692200, (2000).	
BD	* Moore et al., "Tumor angiogenesis is regulated by CXC chemokines", <i>J Lab Clin Med</i> , 132:97-103 (1998)	
BD	* Moore et al., "CXC Chemokine Modulation of angiogenesis...", <i>J Investigative Medicine</i> , vol 46:113-120 (1998)	
EXAMINER <i>B. Dentz</i>	DATE CONSIDERED <i>6-13-2005</i>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).

	ATTY. DOCKET NO.		SERIAL NO.
	25352-0033 D1		10/716,652
	APPLICANT Edgardo Laborde et al.		
	FILING DATE 11/18/2003		GROUP Not Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
BD	* Murphy, "The Molecular Biology of Leukocyte Chemoattractant Receptors", <i>Annu Rev Immun</i> , 12:593-633, (1994)		
BD	* Nelken et al., "Monocyte Chemoattractant Protein-1 in Human Atheromatous Plaques", <i>J. Clin Invest</i> , 88:1121-1127 (1991)		
BD	* Okada et al., "Synthesis and Antitumor Activities of Water-Soluble Benzoylphenylureas", <i>Chem Pharm Bull</i> , 47:430-433, (1999)		
BD	* Okada et al., "Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas", <i>Chem Pharm Bull</i> 42:57-61, (1994)		
BD	* Okada et al., "Synthesis and Antitumor Activities of Novel Benzoylphenylurea Derivatives", <i>Chem Pharm Bull</i> , 39:2308-2315 (1991)		
BD	* Proost et al., "The Role of Chemokines in Inflammation", <i>Int J Clin Lab Res</i> , 26:211-223, (1996)		
BD	* Robinson et al., "Chemokine expression in Rheumatoid Arthritis...", <i>Clin Exp Immunol</i> 101:398-407 (1995)		
BD	* Rollins, "Chemokines", <i>Blood</i> , vol 90 no. 3, pp. 909-928, August 1, 1997		
BD	* Rousseau, Jean-Francois et al., Chemical Abstract, "Regioselective ortho-directed metalation and electrophilic substitution of indole and indoling -5-(N-phenyl) carboxamides" retrieved from STN database accession no. 136:355126 XP002206081 abstract & Heterocycles 92001, 55(12), 2289-2304		
BD	* Rovin et al., "Chemotactic Factors and Renal Inflammation", <i>American Journal of Kidney Diseases</i> , 31:1065-1084, June 1998		
BD	* Rovin, "Chemokines as Therapeutic Targets in Renal Inflammation", <i>American Journal of Kidney Diseases</i> , 34: 761-767, October 1999		
BD	* Rovin, "Chemokine blockade as a therapy for renal disease", <i>Current Opinion in Nephrology and Hypertension</i> , 13:225-232, (2000)		
BD	* Rovin et al., "A Novel Polymorphism in the MCP-1 Gene Regulatory Region That Influences MCP-1 Expression", <i>Biochemical and Biophysical Research Communications</i> , 259, pp. 344-348, (1999)		
BD	* Saunders and Tarby, "Opportunities for novel therapeutic agents acting at chemokine receptors", <i>Drug Discovery Today</i> , vol. 4 No. 2 (1999)		
BD	* Schall, "Biology of the RANTES/SIS Cytokine Family", <i>Cytokine</i> , 3:165-183, (1991)		
BD	* Sendo et al., "Regulation of leukocyte adherence and migration by glycosylphosphatidyl-inositol-anchored proteins", <i>Journal of Leukocyte Biology</i> , vol. 66, pp. 369-374, September 1999		
BD	* Servant et al., "Polarization of Chemoattract Receptor Signaling During Neutrophil Chemotaxis", <i>Science</i> , vol. 287: 1037-1040, February 11, 2000		
BD	* Strieter et al., "The Immunopathology of Chemotactic Cytokines: The Role of Interleukin-8 and Monocyte Chemoattractant Protein-1", <i>J Lab Clin Med</i> , 123:183-197 (1994)		
BD	* Sugiyama et al., "Chemokines in Bronchoalveolar Lavage Fluid in Summer-type Hypersensitivity Pneumonitis", <i>Eur Respir J</i> , 8:1084-1090 (1995)		
EXAMINER		DATE CONSIDERED 6-13-2005	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b>  <b>PTO-1449</b>	<b>ATTY. DOCKET NO.</b> 25352-0033 D1	<b>SERIAL NO.</b> 10/716,652
	<b>APPLICANT</b> Edgardo Laborde et al.	
	<b>FILING DATE</b> 11/18/2003	<b>GROUP</b> Not Assigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
BD	* Szekanecz et al., "Cytokines in Rheumatoid Arthritis", <i>Drugs and Aging</i> , 12:377-390, May 12, 1998	
BD	* Taub, D.D. "Chemokine-Leukocyte Interactions", <i>Cytokine Growth Factor Rev</i> , 7:355-376, (1996)	
BD	* Takeya et al., "Detection of Monocyte Chemoattractant Protein-1 in Human Atherosclerotic Lesions by an Anti-monocyte Chemoattractant Protein-1 Monoclonal Antibody", <i>Human Pathol</i> , 24:534-539 (1993)	
BD	* Tanaka et al., "T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 $\beta$ ", <i>Nature</i> , 361:79-82 (1993)	
BD	* Trivedi et al., "Chemokines: Targets for novel therapeutics", <i>Annual Reports in Medicinal Chemistry</i> , 35:191-200, (2000)	
BD	* Vaddi and Newton, "Comparison of biological responses of human monocytes and THP-1 cells to chemokines to the intercrine- $\beta$ family", <i>Journal of Leukocyte Biology</i> , vol 55: 756-761, June 1994	
BD	* Villiger et al., "Production of Monocyte Chemoattractant Protein-1 By Inflamed Synovial Tissue and Cultured Synoviocytes", <i>J Immunol</i> , vol. 149, pp. 722-727, (1992)	
BD	* Vlodavsky et al., "Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor", <i>Cancer and Metastasis Reviews</i> 15: 177-186, (1996)	
BD	* Waltenberger et al., "Suramin is a Potent Inhibitor of Vascular Endothelial Growth Factor. A Contribution to the Molecular Basis of its Antiangiogenic Action", <i>J Mol Cell Cardiol</i> , 28:1523-1529, (1996)	
BD	* Wang et al, "Chemokines and their role in tumor growth and metastasis", <i>Journal of Immunological Methods</i> , 220: 1-17, (1998)	
BD	* Wellstein and Czubayko, "Inhibition of fibroblast growth factors", <i>Breast Cancer Res Treat</i> , 38:109-119 (1996)	
BD	* White, "Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration", <i>J. Bio Chem</i> , 273:10095-10098 (1998)	
BD	* Wrenshall et al., "Modulation of macrophage and B cell function by glycosaminoglycans", <i>Journal of Leukocyte Biology</i> , vol. 66:391-400, September 1999	
BD	* Yang et al., "Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states", <i>Journal of Leukocyte Biology</i> , vol. 66: 401-410, September 1999	
BD	* Yla-Herttuala et al., "Expression of Monocyte Chemoattractant Protein 1 in Macrophage-Rich Areas of Human and Rabbit Atherosclerotic Lesions", <i>Proc Natl Acad Sci USA</i> , 88:5252-5256 (1991)	
BD	* Zetzsche et al., Crossfire Beilstein 'Online' Beilstein Institut Aur Forerderung Der Wissenschaften, Frankfurt, DE; Abstract, Chemische Berichte, vol. 72, 1939, page 1599	
<b>EXAMINER</b> <i>B. Dantz</i>	<b>DATE CONSIDERED</b> <i>6-13-2005</i>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).